#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukodystrophy Squamous cell carcinoma of the hypopharynx Follicle centre lymphoma follicular grade I II – III refractory Sexually transmitted disease Hepatitis D Neutropenia Raynaud's phenomenon Guillain-Barre syndrome Glioma Liver transplant rejection Advanced systemic mastocytosis Cytokine release syndrome Familial amyotrophic lateral sclerosis Bulbospinal muscular atrophy congenital Sickle cell disease More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Basic Information Rhabdoid tumour – Diagnostics Angelman’s syndrome – Treatment Adrenogenital syndrome Ocular melanoma – Treatment Epidermolysis bullosa Mastocytosis – Treatment Crigler-Najjar syndrome – Basic Information Atypical haemolytic uraemic syndrome Mucopolysaccharidosis III – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Prasugrel Azenosertib Enlicitide Chloride Ertapenem Sodium Nebivolol GSKVX000000034792 Osteodex Somapacitan Pf-06835375 VERT-002 Specific Nucleic Acid Sna-Her1 Digoxin Thiocolchicoside Quetiapine Iclepertin Glutathione SALICYLIC ACID LY3537021 Clemastine Fumarate IG-TREGS More therapies…

    Learn about Your Condition

    Cervix carcinoma stage IV Caesarean section Herpes simplex meningitis Leiomyosarcoma Renal failure Neuroblastoma recurrent Chondrosarcoma metastatic Embolism Endolymphatic hydrops T-cell type acute leukaemia Erythema COVID-19 Liposarcoma Short-bowel syndrome Metastases to peritoneum More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Genetic Phenomena

  • Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

    Not recruiting

    3 1
    Investigated Diseases:
    • Familial hypertriglyceridaemia
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Austria Belgium Croatia France Ireland Poland +1

  • Study on Gene Therapy with Atidarsagene Autotemcel for Patients with Metachromatic Leukodystrophy

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Metachromatic leukodystrophy
    Investigated Drugs:
    • Atidarsagene Autotemcel
    Italy

  • Study on the Safety of Donidalorsen for Patients with Hereditary Angioedema

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Donidalorsen
    The Netherlands

  • Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

    Not recruiting

    3 1
    Investigated Diseases:
    • Osteochondrodysplasia
    Investigated Drugs:
    • Infigratinib
    France Germany Italy Norway Spain

  • Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Neuromyelitis optica spectrum disorder
    Investigated Drugs:
    • Ravulizumab
    France Italy Spain

  • Study on Long-Term Safety of Donidalorsen for Patients with Hereditary Angioedema

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Donidalorsen
    Belgium Bulgaria France Germany Italy The Netherlands +2
Previous Page
1 2 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!